BioSpace

Sellas’ cancer vaccine slashes death risk by 41% in late-stage AML study

Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia.

By BioSpace

1 min read
Sellas’ cancer vaccine slashes death risk by 41% in late-stage AML study
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights